China pharma holdings, inc

China Pharma Holdings, Inc. Announces SFDA Approval
For Production of Omeprazole Injections
Broadens Product Offerings for Multiple Therapeutic Markets –
HAIKOU CITY, China, August 18, 2009 - China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin
Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China,
today announced that it has received approval from the Chinese State Food and Drug Administration
(“SFDA) for the production of generic Omeprazole Sodium injections.
Omeprazole is widely utilized to treat gastroesophageal reflux disease (ghly effective in
other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent
duodenal ulcers and Zollinger-Ellison Syndrome.
Omeprazole is a gastric proton pump inhibitor. This product is a substituted benzimidazole derivative
which acts on the final step of gastric acid production and therefore controls acid secretion in response to
all varieties of stimuli. Omeprazole was first marketedr the brand names
Losec and Prilosec(it is estimated that patients have benefited from over 900million treatments since its
launch1), and is now also available fromufacturers under various brand names. Omeprazole
is on China’s National Medical Reimbursement Insurance List, allowing insured patients to receive
reimbursement for the cost of injections, and has been included in the WHO (World Health Organization)
Model List of Essential Medicines in March 2009.
China Pharma's CEO and President, Ms Zhilin Li, commented, "We are very pleased that the SFDA has
approved China Pharma’s production of Omeprazole Sodium injections. Omeprazole, a selective
inhibitor for gastric acid secretion, is one of the most widely prescribed drugs in the world today2. The
market of gastrointestinal (GI) disorders is one of the largest and most profitable therapeutic areas for the
global pharmaceutical industry. With a reported $49.9bn in revenue in 2007 worldwide, GI diseases
consistently ranks with cardiovascular diseases and oncology in the top 3 therapeutic areas in terms of
market value3. While most oral Omeprazole preparations are enteric-coated due to the rapid degradation
of the drug in the acidic conditions of the stomach; our injection product is formulated in freeze-dried
powder, as a result, it enters the blood circulation faster and works efficiently toward absorption and
avoiding degradation.”
Ms. Li continued, “We believe that this approval provides us with an exciting opportunity to extend our
product portfolio, and we expect it to create value for our patients and shareholders over time.”
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that
develops, manufactures, and markets treatments for a wide range of high incidence and high mortality
conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's
cost-effective, high margin business model is driven by market demand and supported by eight scalable
GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and
expanding distribution network across 30 provinces, municipalities and autonomous regions. The
Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson),
located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings,
Inc. For more information about China Pharma Holdings, Inc., please
visit .


Safe Harbor Statement Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations. 1. Source: Astrazeneca Annual Report And Form 20-F Information 2008 2 Source: Analytica Chimica Acta 2009Vol.633( “Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases” 3. Source: World Gastrointestinal Disorders Market 2008-2023

Source: http://www.chinapharmaholdings.com/News/2009/August%2019,%202009.pdf